Sanders Investigates a $375,000 Price Spike on Old Drug
WASHINGTON, Feb. 4 – In a letter sent Monday to the CEO of Catalyst Pharmaceuticals, Sen. Bernie Sanders (I-Vt.) demanded the company explain its decision to set the price of Firdapse, a drug used to treat a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome (LEMS), at $375,000 per year. For two decades, patients have received the same drug โ known